Eva Medtec

Automated Lymphatic Therapy (ALT) Technology

Print
Claim My Business
Security Type
Common Stock
Min Investment
$99
Location
Bloomington, MN
Offering Date
December 20, 2022
Expected Close Date
June 30, 2023
Target Raise
$10.00K-$487.50K
No. Investors
47
Security Price
$1.50
Valuation
$11,247,279
Website
evamedtec.com
Number of Employees
5
Cash
$41,261
Revenue
$54,140
Short Term Debt
$141,736
Cost of Goods
$17,807
Long Term Debt
$0
Net Income
$-268,450

Company Description

Eva Medtec is a medical technology enterprise that launched commercially in 2021 with its flagship product, the Neuroglide™, and has raised $3.7M to date.

Key Deal Facts

The Neuroglide™ by Eva Medtec makes it possible for anyone to experience the benefits of automated lymphatic therapy with one simple, at-home system. The company’s proprietary technology has received FDA-clearance for pain relief and increased circulation, which has numerous physical health benefits.

By developing non-invasive solutions that can be accessed without the need for a prescription, Eva Medtec is targeting the $4B Pain Management Devices market, which is expected to reach more than $8.5B by 2030 (8.5% CAGR). With additional therapy attachments currently in development, Eva Medtec also plans to address the $18.6B Stress Management Market as well as the $30B+ Sleep Health Market as the company looks to expand the Neuroglide’s FDA labeling.*

At the helm of Eva Medtec’s operations is a team of passionate founders with decades of combined medical and marketing experience seeking to continually evolve the company’s product pipeline with new innovations for the med-tech market. All products developed by Eva Medtec are based on extensive in-field expertise and are made in the U.S. by a full, in-house manufacturer.

Management Team / Advisory Board Bios

John Foster DinussonPresident & CEOJohn was the Founder and President of OrthoCor Medical, which was acquired by Caerus Crop. He brings over 25 years of leadership in diverse areas, including venture capital, finance and operations. John’s primary experience was at Blumberg Capital, an early-stage venture capital firm that specializes in leading Seed and Series A rounds in syndication with angels, venture capital firms and strategic investors. John led Initiative Ventures where he worked with early stage Minnesota based ventures. He has worked with many successful start-up companies in obtaining financing and in their growth efforts. He currently works in an advisory capacity with several early stage companies.
Irene Anne Waldridge Founder/CTO Irene Waldridge, Founder & CTO. Irene Waldridge is a seasoned executive and entrepreneur with over 27 years inventing medical devices. She is the Founder of two companies, Tactile Medical and Eva Medtec. At Tactile Medical, Irene invented and developed the Flexitouch device for treating lymphedema and venous insufficiency. She has held a variety of executive positions, including CEO, Chairman of the Board and CTO. She is also the inventor of the FDA-cleared, OTC, Neuroglide™ Pain Relief and Recovery System to help patients with acute/chronic pain, and increase lymphatic circulation for the removal of harmful cellular waste from the body's soft tissues. 
David Edward RuppVP of MarketingMr. Rupp spent 15+ years as a National Marketing Manager where he planned, created, and directed the department’s strategic plan and oversaw planning and implementation of 5 national product lines that saw company wide sales more than triple in 4 years.
Toni May HastingsVP of Administration20 years of experience working with pain management clinics, and 5 years of experience with Class II medical devices, R&D and manufacturing/operations., Mark Melin, MDMedical DirectorM. Mark Melin MD FACS RPVI FACCWS, is a surgeon and Medical Director of the M Health Wound Healing Institute (South Campus) and an Adjunct Associate Professor in the University of Minnesota Surgical Department. His interests and educational niches include management of lymphedema/lymphatic stasis in the wounded patient, the endothelial glycocalyx, adjunctive micronutrient and bionutrient application to wound care, diosmin Micronized Purified Flavonoid Fraction (MPFF), polygenic abnormality impact upon wound resolution, wound pH and biofilm management, and emerging technologies in wound products and wound technologies.
Dan Sipple, DOMedical AdvisorDr. Daniel Sipple is board certified in physical medicine and rehabilitation with sub-specialty board certification in pain medicine. He trained at the Rehabilitation Institute of Chicago, now the Shirley Ryan Ability Lab, the #1 rated rehabilitation hospital in US News and World Report over 20 years running. He served on faculty at Northwestern University Medical School while working at RIC’s American Academy of Pain Medicine Center of Excellence. He subsequently practiced in Denver Colorado for two years, working along side former team physicians of the Denver Broncos and Colorado Rockies. Thereafter, at the Mayo Clinic in Eau Claire, Wisconsin via the Pain Clinic of NW Wisconsin. He served as the medical director the Health East Spine Center, and service line medical director over Neurosurgery, Behavioral Health, Pain and Spine for the health system. Dr. Sipple is the co-founder of InSitu Biologics, and co-inventor of INSB 200, sustained release non-opiate pain killer for post operative pain set to enter phase I FDA clinical trials in 2022. He is the patent holder in safe needle technology and the founder of Acies Medical. He served on the Board of Directors for the Society for Brain Mapping and Therapeutics, a NASA Spinout, and part of President Obama’s BRAIN Initiative.
Doug Goldstein, DPTMedical AdvisorDoug earned his Doctorate in Physical Therapy from The University of Colorado School of Medicine – Physical Therapy Program. His primary focus is in orthopedics where he is both board certified and fellowship trained. His specialization is performance enhancement and advises athletes from the NFL, NBA, USA Men’s/Women’s Soccer, MLS, MLB, UFC, USA Track and Field. He most recently founded Launchpad Fitness which utilizes AI computer vision to provide youth athletes performance training.
Amount Raised : $1,430
Reveal the Score by Voting
_
Additional ratings from other users are needed to determine a viable CrowdScore for this deal.
The "CrowdScore" for this deal is determined by user ratings and other factors using our proprietary algorithm.
The overall viability and scalability of the business concept as well as the ability to drive the concept to profitability over time.
Business Idea
The progress made thus far in demonstrating that the business has viability, a customer base or other business traction.
Business Traction
The experience of the management team in running, scaling and/or exiting a business that required similar skills to execute the business plan.
Management Team
The value of the company compared to similar companies raising money from investors.
Valuation

Security Description

Common stock is a security that represents ownership in a corporation.

Research Reports

No reports have been submitted

Become a Reporter

0 Comments